Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 6, 2008, Pages 937-948

  Mauritz, Robert ^a   Peters, Godefridus J ^a   Kathmann, Ietje ^a   Teshale, Habte ^a   Noordhuis, Paul ^a   Comijn, Elizabeth M ^a   Pinedo, Herbert M ^a   Jansen, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifolates; Leukaemia cells; Membrane folate receptor; Methotrexate; Polyglutamylation; Reduced folate carrier; Thymidylate synthase

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; AMINOPTERIN; BGC 9331; DIHYDROFOLATE REDUCTASE INHIBITOR; EDATREXATE; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID ANTAGONIST; GS 7904 L; GW 1843; MEMBRANE RECEPTOR; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PLEVITREXED; PT 644; RALTITREXED; REDUCED FOLATE CARRIER; THYMIDINE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPLETION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOLECULAR DYNAMICS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPORT KINETICS; VITAMIN INTAKE;

ANIMALS; ASCITIC FLUID; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; FOLIC ACID ANTAGONISTS; FOLIC ACID DEFICIENCY; LEUKEMIA L1210; MAXIMUM TOLERATED DOSE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED DBA; NEOPLASM PROTEINS; POLYGLUTAMIC ACID; RECEPTORS, CELL SURFACE; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 51849092058     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0683-0     Document Type: Article

References (71)

1. Aherne GW, Brown S (1999) The role of uracil misincorporation in thymineless death. In: Jackman AL (ed) Antifolate drugs in cancer therapy. Humana Press, Totowa, pp 409-421
2. RG Anderson BA Kamen KG Rothberg SW Lacey 1992 Potocytosis: sequestration and transport of small molecules by caveolae Science 255 410 411
3. YG Assaraf 2006 The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis Drug Resist Updat 9 227 246
4. YG Assaraf 2007 Molecular basis of antifolate resistance Cancer Metastasis Rev 26 153 181
5. VM Belkov EY Krynetski JD Schuetz Y Yanishevski E Masson S Mathew S Raimondi CH Pui MV Relling WE Evans 1999 Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation Blood 93 1643 1650
6. TS Benepal I Judson 2005 ZD9331: discovery to clinical development Anticancer Drugs 16 1 9
7. BJ Braakhuis G Jansen P Noordhuis A Kegel GJ Peters 1993 Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma Biochem Pharmacol 46 2155 2161
8. E Chu MA Callender MP Farrell JC Schmitz 2003 Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52 Suppl 1 S80 S89
9. G Cocconi D Cunningham E Van Cutsem E Francois B Gustavsson G Van Hazel D Kerr K Possinger SM Hietschold 1998 Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group J Clin Oncol 16 2943 2952
10. PD Cole RA Drachtman AK Smith S Cate RA Larson DS Hawkins J Holcenberg K Kelly BA Kamen 2005 Phase II trial of oral aminopterin for adults and children with refractory acute leukemia Clin Cancer Res 11 8089 8096
11. PD Cole JA Zebala MJ Alcaraz AK Smith J Tan BA Kamen 2006 Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy Cancer Chemother Pharmacol 57 826 834
12. G Corona F Giannini M Fabris G Toffoli M Boiocchi 1998 Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells Int J Cancer 75 125 133
13. DS Duch S Banks IK Dev SH Dickerson R Ferone LS Heath J Humphreys V Knick W Pendergast S Singer 1993 Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase Cancer Res 53 810 818
14. H Elnakat M Ratnam 2004 Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy Adv Drug Deliv Rev 56 1067 1084
15. DD Gibbs DS Theti N Wood M Green F Raynaud M Valenti MD Forster F Mitchell V Bavetsias E Henderson AL Jackman 2005 BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors Cancer Res 65 11721 11728
16. M Hazarika RM White Jr BP Booth YC Wang DY Ham CY Liang A Rahman JV Gobburu N Li R Sridhara DE Morse R Lostritto P Garvey JR Johnson R Pazdur 2005 Pemetrexed in malignant pleural mesothelioma Clin Cancer Res 11 982 992
17. GB Henderson EM Zevely 1984 Transport routes utilized by L1210 cells for the influx and efflux of methotrexate J Biol Chem 259 1526 1531
18. JH Hooijberg HJ Broxterman M Kool YG Assaraf GJ Peters P Noordhuis RJ Scheper P Borst HM Pinedo G Jansen 1999 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 Cancer Res 59 2532 2535
19. AL Jackman AH Calvert 1995 Folate-based thymidylate synthase inhibitors as anticancer drugs Ann Oncol 6 871 881
20. AL Jackman IR Judson 1996 The new generation of thymidylate synthase inhibitors in clinical study Expert Opin Investig New Drugs 5 719 736
21. AL Jackman R Kimbell GW Aherne L Brunton G Jansen TC Stephens MN Smith JM Wardleworth FT Boyle 1997 Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331-a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase Clin Cancer Res 3 911 921
22. AL Jackman GA Taylor AH Calvert KR Harrap 1984 Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717 Biochem Pharmacol 33 3269 3275
23. AL Jackman GA Taylor W Gibson R Kimbell M Brown AH Calvert IR Judson LR Hughes 1991 ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study Cancer Res 51 5579 5586
24. AL Jackman DS Theti DD Gibbs 2004 Antifolates targeted specifically to the folate receptor Adv Drug Deliv Rev 56 1111 1125
25. Jansen G (1999) Receptor- and carrier-mediated transport systems for folates and antifolates-exploitation for folate-based chemotherapy and immunotherapy. In: Jackman AL (ed) Antifolate drugs in cancer therapy. Humana Press, Totowa, pp 293-321
26. G Jansen I Kathmann BC Rademaker BJ Braakhuis GR Westerhof G Rijksen JH Schornagel 1989 Expression of a folate binding protein in L1210 cells grown in low folate medium Cancer Res 49 1959 1963
27. G Jansen R Mauritz S Drori H Sprecher I Kathmann M Bunni DG Priest P Noordhuis JH Schornagel HM Pinedo GJ Peters YG Assaraf 1998 A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance J Biol Chem 273 30189 30198
28. Jansen G, Westerhof GR, Kathmann I, Rademaker BC, Rijksen G, Schornagel JH (1989) Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance [published erratum appears in Cancer Res 1995 Sep 15;55(18):4203]. Cancer Res 49:2455-2459
29. BA Kamen A Capdevila 1986 Receptor-mediated folate accumulation is regulated by the cellular folate content Proc Natl Acad Sci USA 83 5983 5987
30. DA Keefe RL Capizzi SA Rudnick 1982 Methotrexate cytotoxicity for L5178Y/Asn-lymphoblasts: relationship of dose and duration of exposure to tumor cell viability Cancer Res 42 1641 1645
31. LH Matherly DI Goldman 2003 Membrane transport of folates Vitam Horm 66 403 456
32. R Mauritz MW Bekkenk MG Rots R Pieters E Mini CH Van Zantwijk AJP Veerman GJ Peters G Jansen 1998 Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells Clin Cancer Res 4 2399 2410
33. DE McCloskey JJ McGuire CA Russell BG Rowan JR Bertino G Pizzorno E Mini 1991 Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines J Biol Chem 266 6181 6187
34. JJ McGuire P Hsieh JK Coward JR Bertino 1980 Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products J Biol Chem 255 5776 5788
35. E Mini S Srimatkandada WD Medina BA Moroson MD Carman JR Bertino 1985 Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells Cancer Res 45 317 324
36. RG Moran 1999 Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview Semin Oncol 26 24 32
37. C Niyikiza AR Hanauske JJ Rusthoven AH Calvert R Allen P Paoletti PA Bunn Jr 2002 Pemetrexed safety and dosing strategy Semin Oncol 29 24 29
38. GJ Peters G Jansen 2001 Folate homeostasis and antiproliferative activity of folates and antifolates Nutrition 17 737 738
39. GJ Peters CL Vander Wilt 1995 Thymidylate synthase as a target in cancer chemotherapy Biochem Soc Trans 23 884 888
40. GJ Peters CL Vander Wilt B Van Triest G Codacci-Pisanelli PG Johnston CJ Van Groeningen HM Pinedo 1995 Thymidylate synthase and drug resistance Eur J Cancer 31A 1299 1305
41. H Qi M Ratnam 2006 Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates Cancer Res 66 5875 5882
42. A Qiu M Jansen A Sakaris SH Min S Chattopadhyay E Tsai C Sandoval R Zhao MH Akabas ID Goldman 2006 Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption Cell 127 917 928
43. A Qiu SH Min M Jansen U Malhotra E Tsai DC Cabelof LH Matherly R Zhao MH Akabas ID Goldman 2007 Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction Am J Physiol Cell Physiol 293 C1669 C1678
44. M Ratnam H Marquardt JL Duhring JH Freisheim 1989 Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA Biochemistry 28 8249 8254
45. MS Rhee J Galivan EM Tyobeka ML Sherman A Rosowsky 1993 Effect of a novel antifolate, N alpha-(4-amino-4-deoxypteroyl)-N delta- hemiphthaloyl-l-ornithine (PT523), on growth of H35 rat hepatoma and HEPG2 human hepatoma cells Adv Exp Med Biol 338 461 464
46. MS Rhee J Galivan JE Wright A Rosowsky 1994 Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells Mol Pharmacol 45 783 791
47. S Rijnboutt G Jansen G Posthuma JB Hynes JH Schornagel GJ Strous 1996 Endocytosis of GPI-linked membrane folate receptor-alpha J Cell Biol 132 35 47
48. S Rodenhuis JJ McGuire R Narayanan JR Bertino 1986 Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells Cancer Res 46 6513 6519
49. A Rosowsky 1999 PT523 and other aminopterin analogs with a hemiphthaloyl-l-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates Curr Med Chem 6 329 352
50. MG Rots R Pieters GJ Peters P Noordhuis CH Van Zantwijk G Henze GE Janka-Schaub AJ Veerman G Jansen 2000 Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia Br J Haematol 109 629 634
51. BG Rumberger JR Barrueco FM Sirotnak 1990 Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action Cancer Res 50 4639 4643
52. MD Salazar M Ratnam 2007 The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26 141 152
53. GV Scagliotti C Kortsik GG Dark A Price C Manegold R Rosell M O'Brien PM Peterson D Castellano G Selvaggi S Novello J Blatter L Kayitalire L Crino L Paz-Ares 2005 Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial Clin Cancer Res 11 690 696
54. JC Schmitz GB Grindey RM Schultz DG Priest 1994 Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity Biochem Pharmacol 48 319 325
55. JH Schornagel J Verweij PH De Mulder F Cognetti JB Vermorken P Cappelaere JP Armand J Wildiers A De Graeff Clavel 1995 Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study J Clin Oncol 13 1649 1655
56. C Shih VJ Chen LS Gossett SB Gates WC MacKellar LL Habeck KA Shackelford LG Mendelsohn DJ Soose VF Patel SL Andis JR Bewley EA Rayl BA Moroson GP Beardsley W Kohler M Ratnam RM Schultz 1997 LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 1116 1123
57. Sirotnak FM, Schmid FA, Samuels LL, DeGraw JI (1987) 10-Ethyl-10-deaza- aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. NCI Monogr 127-131
58. A Smith MC Hum NJ Winick BA Kamen 1996 A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro Clin Cancer Res 2 69 73
59. MJ Spinella KE Brigle SJ Freemantle EE Sierra ID Goldman 1996 Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects Biochem Pharmacol 52 703 712
60. MJ Spinella KE Brigle EE Sierra ID Goldman 1995 Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells J Biol Chem 270 7842 7849
61. DS Theti V Bavetsias LA Skelton J Titley D Gibbs G Jansen AL Jackman 2003 Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor Cancer Res 63 3612 3618
62. CL Van der Wilt HH Backus K Smid L Comijn G Veerman D Wouters DA Voorn DG Priest MA Bunni F Mitchell AL Jackman G Jansen GJ Peters 2001 Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors Cancer Res 61 3675 3681
63. J Walling 2006 From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates Invest New Drugs 24 37 77
64. X Wang F Shen JH Freisheim LE Gentry M Ratnam 1992 Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates Biochem Pharmacol 44 1898 1901
65. SD Weitman RH Lark LR Coney DW Fort V Frasca VR Zurawski Jr BA Kamen 1992 Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues Cancer Res 52 3396 3401
66. GR Westerhof G Jansen N Van Emmerik I Kathmann G Rijksen AL Jackman JH Schornagel 1991 Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems Cancer Res 51 5507 5513
67. GR Westerhof S Rijnboutt JH Schornagel HM Pinedo GJ Peters G Jansen 1995 Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein Cancer Res 55 3795 3802
68. GR Westerhof JH Schornagel I Kathmann AL Jackman A Rosowsky RA Forsch JB Hynes FT Boyle GJ Peters HM Pinedo G Jansen 1995 Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity Mol Pharmacol 48 459 471
69. JC Yalowich TI Kalman 1985 Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro Biochem Pharmacol 34 2319 2324
70. Zervos PH, Allen RH, Thornton DE, Thiem PA (1997) Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer 33(Suppl 18)
71. R Zhao F Gao M Hanscom ID Goldman 2004 A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier Clin Cancer Res 10 718 727